Accumetrics Announces Publication of GRAVITAS Primary Results in JAMA

By Accumetrics Inc., PRNE
Monday, March 14, 2011

Evaluation of Alternative Treatment Strategies Incorporating Platelet Function Testing Recommended

SAN DIEGO, March 15, 2011 - Accumetrics, Inc., developer of the VerifyNow(R) System, the first rapid
and easy-to-use point-of-care system for measuring platelet reactivity to
multiple antiplatelet agents, announced today that the primary results of the
GRAVITAS trial have been published in The Journal of the American Medical

First presented at the American Heart Association's Annual Scientific
Sessions in November 2010, the results refute a "one-size fits all" strategy
of uniformly doubling the dose of clopidogrel (Plavix(R)) over six months for
patients with high on-treatment platelet reactivity (low response) after
taking a standard dose of the commonly prescribed antiplatelet drug.

While there was a modest reduction in platelet reactivity in GRAVITAS
patients receiving a 6-month double dose of Plavix compared to the standard
dose, it was not sufficient to impact overall outcomes, leading the authors
to suggest that more potent platelet inhibition may have been beneficial.

Further, and consistent with numerous previous studies, the trial
demonstrated an association between high on-treatment platelet reactivity and
the occurrence of adverse cardiac events such as death, heart attack and
stent thrombosis.

"The GRAVITAS findings do not support a uniform treatment strategy for
patients with high on-treatment platelet reactivity," said Matthew J. Price,
MD, of the Scripps Translational Science Institute and Scripps Clinic in La
Jolla, CA
, lead author of the article and Principal Investigator of the
GRAVITAS trial. "Rather than prescribing a fixed, higher dose of clopidogrel
based on a single post-PCI platelet function test, we need to consider
alternative treatment strategies that incorporate platelet function testing,
such as using more potent antiplatelet agents or repeated testing to a
specific target of reactivity."

The article reports that 41% of patients in the GRAVITAS trial had high
on-treatment platelet reactivity after receiving Plavix(R). This is
consistent with previous studies that show that up to 1 in 3 patients may not
be responding adequately to their antiplatelet therapy. Numerous factors are
associated with low platelet response, including pre-existing health
conditions such as diabetes, interference from other medications, non
compliance and genetics.

"GRAVITAS underscores the need to develop more individualized treatment
strategies for cardiovascular patients," said Timothy I. Still, President and
CEO of Accumetrics. "As more antiplatelet treatment options become available,
the VerifyNow System continues to help clinicians better assess a patient's
response to therapy."

The VerifyNow System is widely used in various clinical settings where
antiplatelet medications are prescribed to reduce the occurrence of future
thrombotic events such as heart attack and stroke.

(1) Price MJ, Berger PB, Teirstein PS, et al. Standard- vs High-Dose
Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary
Intervention. JAMA.2011;305[11]1097-1105.

About Accumetrics

Accumetrics is committed to advancing medical understanding of platelet
function and enhancing quality of care for patients receiving antiplatelet
therapies by providing industry-leading and widely accessible diagnostic
tests for rapid platelet function assessment.

Accumetrics' VerifyNow System is the first rapid and easy-to-use platform
to help physicians determine an individual's response to multiple
antiplatelet agents. Addressing every major antiplatelet drug, including
FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel
(Effient(R)) and clopidogrel (Plavix(R))), and GP IIb/IIIa inhibitors (e.g.
ReoPro(R) and Integrilin(R)), the VerifyNow System provides valuable
information to help physicians make informed treatment decisions. For more
information about the Company and its products, visit

The Accumetrics logo and VerifyNow are registered trademarks of
Accumetrics, Inc. ReoPro is a registered trademark of Centocor, Inc.
Integrilin is a registered trademark of Millennium Pharmaceuticals. Plavix is
a registered trademark of sanofi-aventis. Effient is a registered trademark
of Eli Lilly and Company.

    Jakob Jakobsen

    Timothy I. Still
    President and CEO Accumetrics

Jakob Jakobsen, +1-310-309-1003, Jjakobsen at, for Accumetrics; or Timothy I. Still, President and CEO of Accumetrics, +1-858-404-8260, press at

will not be displayed